ADC Therapeutics Funding: $65M Raised, Series A (2023)

ADC Therapeutics funding overview

ADC Therapeutics has raised $65M in total disclosed funding. That places its disclosed total in the $25M–$100M range. Its most recent disclosed round is a Series A announced in June 2023. The round record for ADC Therapeutics runs through 2023; nothing later has been disclosed. Investors on record include Ysios Capital, Gilde Healthcare, Novartis Venture Fund, New Enterprise Associates, Lightstone Ventures, Meneldor and 1 others. 7 distinct backers are named across the disclosed rounds.

ADC Therapeutics at a glance

Total raised: $65M
Latest round: Series A
Latest round date: June 2023
Notable investors: Ysios Capital, Gilde Healthcare, Novartis Venture Fund, New Enterprise Associates, Lightstone Ventures, Meneldor, Oost NL

Frequently asked about ADC Therapeutics funding

How much has ADC Therapeutics raised?: ADC Therapeutics has raised $65M in total disclosed funding across the rounds on record.
Who has invested in ADC Therapeutics?: Ysios Capital, Gilde Healthcare, Novartis Venture Fund, New Enterprise Associates, Lightstone Ventures, Meneldor are named among the investors backing ADC Therapeutics.
What was the latest ADC Therapeutics funding round?: The most recent disclosed round is a Series A, announced in June 2023.
Where is ADC Therapeutics based?: No headquarters location is disclosed for ADC Therapeutics.
When did ADC Therapeutics last raise?: The last disclosed ADC Therapeutics round closed in June 2023 at Series A.

ADC Therapeutics totals reflect disclosed capital only — undisclosed extensions and secondaries are excluded. Use the related companies below to benchmark round size and investor mix.

ADC Therapeutics Funding: $65M Raised, Series A (2023)

ADC Therapeutics funding overview

ADC Therapeutics at a glance

Frequently asked about ADC Therapeutics funding

Companies related to ADC Therapeutics (14)

Browse related funding lists (7)